News

  • Certara acquires d3 Medicine

    d3 Medicine’s strategic advisory and drug development capabilities expand Certara’s modeling and simulation and regulatory science powerhouse.

    d3
  • Webinar on “Early Development and Translational/Quantitative Pharmacology Strategies in Pediatric Drug Development”

    On 28th July, Craig Rayner and Patrick Smith will provide a Certara Webinar on “Early Development and Translational/Quantitative Pharmacology Strategies in Pediatric Drug Development”.

    d3
  • Craig Rayner delivers 2016 Monash University Graduation Address - "Job, Career or Vocation?"

    “It was a tremendous honour to present the 2016 Graduation Address to Monash University's Faculty of Pharmacy and Pharmaceutical Sciences. I shared experiences from my own journey to highlight insights relating to Job, Career or Vocation," said Craig Rayner, CEO of d3 Medicine.

    Craig Rayner
  • d3 Medicine contributes to Clinical Cancer Research Focus section “New Approaches for Optimizing Dosing of Anticancer Agents”

    In collaboration with colleagues from the Food and Drug Administration (FDA), d3 Medicine published a review of lesson’s learned in dose optimization for small-molecule targeted anti-cancer agents in the June 1 issue of Clinical Cancer Research (CCR).

    Julie Bullock
  • d3 Medicine featured in Nature Biopharma Dealmakers

    d3 Medicine has been featured in Nature Biopharma Dealmakers in an article entitled “A turnkey, integrated solution for drug development strategies and stewardship”.

    d3
  • Translating innovative drug development strategy to value at the deal table

    Dr. Farrell emphasised the importance of earlier and stronger engagement in companies between development and business development teams in his presentation at the GTCBio 13th Anti-Infectives Partnering & Deal-Making Conference in San Diego.

    Leigh Farrell
  • d3 Medicine Congratulates Roche for Alecensa® (Alectinib) FDA Approval in Lung Cancer

    On 11th December, 2015 Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Alecensa® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

    Patrick Smith
  • $10 million for malaria drug development

    Medicines for Malaria Venture (MMV) appointed d3 Medicine LLC to lead an international team of experts to assess QIMR Berghofer Medical Research Institute’s induced human infection model and its potential to accelerate the development of new medicines for malaria globally.
     

    Craig Rayner
  • Medicines Development for Global Health retains d3 Medicine as drug development advisors for moxidectin, a new treatment for onchocerciasis

    Medicines Development for Global Health (MDGH), an Australian not-for-profit biopharmaceutical company, has retained d3 Medicine through an innovative risk-share agreement to provide strategic advice on the development and regulatory strategy to support the registration of moxidectin for onchocerciasis (“River Blindness”).

    Craig Rayner
  • d3 Medicine contributes to landmark RSV study published in the New England Journal of Medicine

    In collaboration with investigators from The University of Tennessee Health Sciences Center, Retroscreen, and Alios Biopharma, d3 Medicine published results of a promising experimental drug in the Nov. 19 issue of the New England Journal of Medicine (NEJM). ALS-008176 is a potent nucleoside analog, which demonstrated significant antiviral activity in healthy adults infected with RSV in a clinical trial.

    Patrick Smith
  • Are you a clinical pharmacologist looking for a new exciting role?

    At d3 Medicine, we’re passionate about helping our clients to Develop Medicines that Matter™ by meeting the needs of patients, regulators, investors and payers.

    Leigh Farrell
  • d3 Medicine presenting at ACoP6

    d3 Medicine and collaborators are pleased to be presenting a session entitled “A Novel Interdisciplinary Pharmacometric Approach: A Systems Approach to Support Pharmacology to the Payer” at the sixth American Conference on Pharmacometrics (ACoP6), to be held in Crystal City, VA, October 4-7, 2015

    Patrick Smith
  • d3 Medicine presenting in AACR/FDA Oncology drug dosing workshop

    The FDA and the American Association for Cancer Research (AACR) are cosponsoring a public workshop titled “Dose-finding of Small Molecule Oncology Drugs.” on May 18-19, 2015.

    Julie Bullock
  • d3 Medicine welcomes Dr. Kashyap Patel

    d3 Medicine is pleased to formalise collaborations with Pharmacometrician, Dr. Kashyap Patel PhD. As Dr. Patel’s existing industry fellowship concludes he will transition to a d3 Medicine-Monash pharmacometrics collaboration.

    Keith Nieforth
  • d3 Medicine supporting antiviral R&D

    d3 Medicine is committed to supporting the development of antivirals with our clients and partners, but also more broadly supporting antiviral R&D.

    d3 Medicine is proud to announce that Regina Dutkowski has been appointed to the Organizing committee of the 4th ISIRV (International Society of Influenza and other Respiratory Viruses) Conference, 2-4 June 2015, Novel Antiviral Therapies for Influenza and other Respiratory Viruses: Bench to Bedside, to be held in Austin, Texas.

    Craig Rayner

Pages